Literature DB >> 16891203

p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma.

Synne Knopp1, Jahn M Nesland, Claes Tropé, Ruth Holm.   

Abstract

The present study addressed the impact of human papillomavirus (HPV), p14, and the product of the retinoblastoma gene (pRb) in vulvar carcinoma in relation to other clinicopathologic variables and prognosis. We immunohistochemically studied 217 primary tumors from patients with vulvar carcinoma for the expression of pRb and p14. By the use of in situ hybridization, the primary tumors and 7 lymph node metastases were studied for the presence of HPV-16, HPV-18, HPV-31, and HPV-33 DNA. HPV-infected cases significantly correlated with high expression of p14 (P < .01) and p16 (P < .01). In HPV- cases with high expression of p53, no p14 expression predicted the poorest disease-specific survival (P < .01). For the first time, we have shown that p14 expression indicates longer disease-specific survival in patients with vulvar carcinoma. In patients with HPV- tumors expressing high levels of p53, low p14 indicated the poorest 5-year disease-specific survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891203     DOI: 10.1309/e9e8y9wg5qe3lk29

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  Cell cycle suppressor proteins are not related to HPV status or clinical outcome in patients with vulvar carcinoma.

Authors:  André Mourão Lavorato-Rocha; Iara Sant'ana Rodrigues; Beatriz de Melo Maia; Mônica Maria Ágata Stiepcich; Glauco Baiocchi; Kátia Cândido Carvalho; Fernando Augusto Soares; José Vassallo; Rafael Malagoli Rocha
Journal:  Tumour Biol       Date:  2013-07-06

2.  Tumor proteomics by multivariate analysis on individual pathway data for characterization of vulvar cancer phenotypes.

Authors:  Annsofi Sandberg; Gunnel Lindell; Brita Nordström Källström; Rui Mamede Branca; Kristina Gemzell Danielsson; Mats Dahlberg; Barbro Larson; Jenny Forshed; Janne Lehtiö
Journal:  Mol Cell Proteomics       Date:  2012-04-12       Impact factor: 5.911

Review 3.  HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.

Authors:  Maura L Gillison; Anil K Chaturvedi; Douglas R Lowy
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

4.  Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.

Authors:  Zhihui Wang; Claes G Trope; Vivi Ann Flørenes; Zhenhe Suo; Jahn M Nesland; Ruth Holm
Journal:  BMC Cancer       Date:  2010-05-25       Impact factor: 4.430

5.  Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis.

Authors:  Zhihui Wang; Ana Slipicevic; Mette Førsund; Claes G Trope; Jahn M Nesland; Ruth Holm
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

6.  Human papillomavirus 16 infection predicts poor outcome in patients with esophageal squamous cell carcinoma.

Authors:  Ruxing Xi; Xiaozhi Zhang; Xin Chen; Shupei Pan; Beina Hui; Li Zhang; Shenbo Fu; Xiaolong Li; Xuanwei Zhang; Tuotuo Gong; Jia Guo; Shaomin Che
Journal:  Onco Targets Ther       Date:  2015-03-05       Impact factor: 4.147

7.  Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Ruth Holm; Mette Førsund; Mai T Nguyen; Jahn M Nesland; Claes G Trope
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

8.  The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas.

Authors:  Zhihui Wang; Claes G Tropè; Zhenhe Suo; Gunhild Trøen; Guanrui Yang; Jahn M Nesland; Ruth Holm
Journal:  BMC Cancer       Date:  2008-10-24       Impact factor: 4.430

9.  Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.

Authors:  Zhihui Wang; Mette S Førsund; Claes G Trope; Jahn M Nesland; Ruth Holm; Ana Slipicevic
Journal:  Cancer Med       Date:  2018-07-02       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.